[{"orgOrder":0,"company":"Almirall","sponsor":"Almirall","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase I","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Almirall \/ Almirall","highestDevelopmentStatusID":"6","companyTruncated":"Almirall \/ Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Controlled Substance","year":"2020","type":"Acquisition","leadProduct":"Diazepam","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Almirall \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Neuraxpharm"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sarecycline","moa":"antibiotics (tetracycline derivatives)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sarecycline","moa":"antibiotics (tetracycline derivatives)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Paratek Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Sarecycline","moa":"antibiotics (tetracycline derivatives)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Almirall \/ Almirall","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Rivastigmine Tartrate","moa":"Cholinesterases; ACHE & BCHE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Almirall","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Oral Capsule","sponsorNew":"Almirall \/ Almirall","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Kelch-like ECH-associated protein 1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pidotimod","moa":"immunomodulators","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Eloxx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ZKN-013","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Almirall","amount2":0.46999999999999997,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.46999999999999997,"dosageForm":"Oral","sponsorNew":"Almirall \/ Almirall","highestDevelopmentStatusID":"5","companyTruncated":"Almirall \/ Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"EpimAb Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Almirall","amount2":0.20999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.20999999999999999,"dosageForm":"Oral","sponsorNew":"Almirall \/ Almirall","highestDevelopmentStatusID":"2","companyTruncated":"Almirall \/ Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Almirall \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Eli Lilly"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Athenex"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Athenex"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Almirall","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Efinaconazole","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Almirall \/ Almirall","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Finasteride","moa":"Steroid 5-alpha-reductase 2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Almirall \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Almirall","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Phase IV","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Almirall","highestDevelopmentStatusID":"11","companyTruncated":"Almirall \/ Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Bioniz Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"BNZ-1","moa":"Interleukin-15 (IL15)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Almirall","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Almirall \/ Almirall","highestDevelopmentStatusID":"7","companyTruncated":"Almirall \/ Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ALM223","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LAD603","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LAD191","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Almirall \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Almirall \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Ichnos Sciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"ISB 880","moa":"IL-1RAP","graph1":"Immunology","graph2":"IND Enabling","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Almirall \/ Almirall","highestDevelopmentStatusID":"5","companyTruncated":"Almirall \/ Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"NN-8828","moa":"Interleukin-21","graph1":"Dermatology","graph2":"Preclinical","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Almirall \/ Almirall","highestDevelopmentStatusID":"4","companyTruncated":"Almirall \/ Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"23andMe","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Almirall \/ Almirall","highestDevelopmentStatusID":"4","companyTruncated":"Almirall \/ Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"HitGen","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Discovery Platform","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Almirall \/ Almirall","highestDevelopmentStatusID":"3","companyTruncated":"Almirall \/ Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"AbSci","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Discovery Platform","graph3":"Almirall","amount2":0.65000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Dermatology","amount2New":0.65000000000000002,"dosageForm":"Topical","sponsorNew":"Almirall \/ Almirall","highestDevelopmentStatusID":"3","companyTruncated":"Almirall \/ Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"University Of Dundee","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Discovery","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Almirall \/ University Of Dundee","highestDevelopmentStatusID":"2","companyTruncated":"Almirall \/ University Of Dundee"},{"orgOrder":0,"company":"Almirall","sponsor":"Etherna","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Almirall","amount2":0.33000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.33000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Almirall \/ Almirall","highestDevelopmentStatusID":"2","companyTruncated":"Almirall \/ Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Almirall \/ Almirall","highestDevelopmentStatusID":"1","companyTruncated":"Almirall \/ Almirall"}]
Find Clinical Drug Pipeline Developments & Deals by Almirall
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
